Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

All Oncology News

Myelopreservation With CDK4/6 Inhibitors

September 9th 2021

Charu Aggarwal, MD, MPH, University of Pennsylvania Hospital

The rationale for using CDK4/6 inhibitors to prevent myelosuppression in patients receiving chemotherapy-containing regimens for extensive-stage small cell lung cancer.

MDS Treatment Selection: Impact of QoL

September 9th 2021

Yazan Madanat, MD, UT Southwestern Medical Center

Drs Madanat and Sekeres comment on the importance of quality of life and patient perspective in the selection of MDS treatment.

Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward

September 8th 2021

Tony Berberabe, MPH

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

Additional Research Efforts Required to Establish New Therapeutic Options for Low-Risk MDS

September 8th 2021

Conor Killmurray

Because standardized treatment approaches have not been established for patients with low-risk myelodysplastic syndromes and limited options are available to those with erythropoietin failure, the need for varied clinical trials is underscored.

TDM-1/Osimertinib Combo Has Limited Efficacy for Resistant EGFR+ NSCLC

September 8th 2021

Jason Harris

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

Dr. Cortes on Emerging Therapies in CML

September 8th 2021

Jorge Cortes, MD

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 8th 2021

Alexey V. Danilov, MD, PhD

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Dr. Patel on the Integration of CAR T-Cell Therapy in Multiple Myeloma

September 8th 2021

Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Selpercatinib Elicits Durable Antitumor Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

Courtney Marabella

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

Sotorasib Induces Intracranial Activity in KRAS G12C–Mutated NSCLC Brain Metastases

September 8th 2021

Jessica Hergert

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

COVID-19 Leads to High Hospitalization and Mortality in Malignant Pleural Mesothelioma

September 8th 2021

Caroline Seymour

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

September 8th 2021

Jackie Collins

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

September 8th 2021

Audrey Sternberg

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

Novel, Emerging Approaches Set the Stage for Advancement in cGVHD

September 8th 2021

Nichole Tucker

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

Antonia DePace

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

See All News